Multicentric evaluation of a second generation assay to detect antiviral citrullinated peptide antibodies: A collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni

Nicola Bizzaro, F. Allegri, C. Alpini, A. Doria, R. Gerli, M. Lotzniker, A. Mathieu, G. Morozzi, F. Bellisai, V. Riccieri, M. Tampoia, P. Migliorini

Research output: Contribution to journalArticlepeer-review

Abstract

Aims: A novel immunoenzymatic assay using viral citrullinated peptides derived from Epstein-Barr virus-encoded proteins (viral citrullinated peptide 2 (VCP2)) has been developed and evaluated by means of a multicentre collaborative study. Methods: Three hundred nine sera from patients with established rheumatoid arthritis (RA), 36 with early arthritis, 12 with juvenile arthritis and 453 controls were tested for VCP2 and cyclic citrullinated peptide (CCP) antibodies. Results: The VCP2 assay showed 78.3% sensitivity and 97.1% specificity. VCP2 and CCP had a high concordance rate in patients with RA (88%) and controls (97%). However, 36 RA sera were positive in the CCP assay but negative on VCP2, and two RA sera reacted only on VCP2. Conclusions: The new VCP2 assay is endowed with high sensitivity and specificity. VCP2-positive RA sera are mostly but not completely contained in the CCP-positive population. Studies are in progress to establish whether the VCP2 assay can detect clinically distinct subsets of patients with RA.

Original languageEnglish
Pages (from-to)1139-1141
Number of pages3
JournalJournal of Clinical Pathology
Volume64
Issue number12
DOIs
Publication statusPublished - Dec 2011

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Multicentric evaluation of a second generation assay to detect antiviral citrullinated peptide antibodies: A collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni'. Together they form a unique fingerprint.

Cite this